Announced

Completed

Biocodex and ATHOS led a €55m Series B round in MRM Health.

Synopsis

Biocodex, an independent French pharmaceutical group, and ATHOS, a Munich-based single family office, led a €55m Series B round in MRM Health, a clinical-stage biopharmaceutical company. “This funding marks a pivotal moment for MRM Health. With the support of our experienced international investor syndicate, we are now well positioned to deliver transformative therapies for patients with chronic inflammatory diseases, where current treatments often fall short. Our CORAL® platform gives us a unique edge in designing potent, resilient and scalable microbiome-based therapeutics. This new funding will allow us to further build both our platform and pipeline,” Sam Possemiers, MRM Health CEO.

Principals

Show Details & Financials

Did you work on this deal?

Claim Deal

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Claim Deal

Sort

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy

All rights reserved. Copyright © 2025 Datasite